Recent Clinical Triumphs Signaling a New Era

Gene therapy has reached pivotal milestones in 2026, with several high-profile approvals and trial successes underscoring its transformative potential. One standout is the FDA's accelerated approval of Kresladi (marnetegragene autotemcel) on March 26 for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I), a rare genetic disorder impairing white blood cell function and leading to recurrent infections. Developed through a UCLA-led clinical trial, this autologous hematopoietic stem cell therapy inserts functional copies of the ITGB2 gene, restoring CD18 expression on neutrophils. Trial data showed sustained improvements in immune biomarkers for up to 24 months, offering a lifeline where matched donor transplants were unavailable. For the roughly one-in-a-million affected children, this means fewer life-threatening infections and a shot at normal childhood activities.FDA announcement

Similarly, Novartis's intrathecal onasemnogene abeparvovec (OAV101 IT) shone in the phase 3 STEER trial for treatment-naive spinal muscular atrophy (SMA) patients aged 2 to under 18 who could sit but not walk. Delivered via lumbar puncture, this adeno-associated virus (AAV9) vector carries the SMN1 gene to counter motor neuron loss. The trial met its primary endpoint with a 1.88-point Hammersmith Functional Motor Scale-Expanded (HFMSE) improvement over sham control (P=0.0074), evident by week 4 and sustained at 52 weeks. Secondary gains in upper limb function further highlight its broad impact across ages, led by investigators from Peking University and University of Cape Town among others. Safety mirrored sham groups, with transient transaminase rises but no severe adverse events of special interest.

CRISPR Precision Editing: University Labs Lead the Charge

CRISPR technologies dominate recent gene therapy research, with universities pioneering compact, efficient systems for safer delivery. The enhanced TnpB-ωRNA (enTnpB) system, detailed in Nature Communications, packs CRISPR-like editing into a single AAV for versatile genome regulation. This compact tool enables ImmunAct, a regimen activating endogenous cytokines to boost cancer immunotherapy without exogenous cell engineering. Researchers demonstrated potent anti-tumor effects in models, sidestepping manufacturing hurdles of CAR-T therapies.

Another leap is the TIGER (Template-Independent Genome Editing for Restoration) platform from Chinese teams, correcting frameshift mutations sans repair templates to restore hearing in DFNB23 mouse models. Published in 2026, TIGER uses CRISPR-Cas9 nickases for precise indels, mimicking natural repair— a game-changer for 10% of genetic hearing losses. Early human trials for OTOF-mediated deafness, using AAV-OTOF, restored audition in children, with auditory brainstem responses improving dramatically post-injection.enTnpB study

• Compact editors like enTnpB reduce AAV cargo limits, enabling multi-gene therapies.
• TIGER's template-free approach minimizes off-targets, ideal for auditory neurons.
• OTOF trials: 5 children gained hearing comparable to cochlear implants.

AAV Innovations Tackle Neurological and Sensory Deficits

Adeno-associated viruses (AAVs) remain workhorses, refined by academic labs for tissue specificity. In LRAT-associated retinitis pigmentosa, a patient-derived rat model tested AAV-mediated gene replacement, restoring visual cycle function and retinal morphology—proof-of-concept from Dutch researchers at Amsterdam UMC.

For methylmalonic acidemia (MMA), a phase 1/2 trial reported first-in-human nuclease-free homologous recombination editing, safely boosting enzyme activity in pediatric livers. Led by U Cincinnati and others, it highlights prime editing's precision over nucleases.

Sickle Cell and Beyond: Editing Blood Disorders

Cleveland Clinic's RUBY trial with reni-cel (CRISPR/Cas12a-edited stem cells) achieved functional cures in 27/28 severe sickle cell patients—no crises post-treatment, hemoglobin rising to 13.8 g/dL with 48% fetal hemoglobin. This builds on Casgevy, expanding CRISPR to broader hemoglobinopathies via university-honed editors.

Overcoming Delivery Hurdles: Endosomal Escape and Targeting

New lysosomal barcoding tracks nucleic acid escape in vivo, optimizing lipid nanoparticles for liver delivery—key for 70% of trials. Focused ultrasound broadens AAV-Cas9 spread, while antibody-guided vectors target suicide genes to antigens.

Risks include immunogenicity and off-targets, but codon-optimized Smad7 boosts dystrophin models' muscle without inflammation.

Challenges Persist: Safety, Scalability, and Equity

2026 saw pauses like UKRI funding cuts, yet momentum builds with FDA frameworks for ultra-rares. Hepatotoxicity and dorsal root ganglion issues demand vigilant monitoring, as in STEER.

University Research Fueling the Pipeline

Institutions like UCLA (LAD-I), Cleveland Clinic (sickle cell), Peking U (SMA), and Chinese labs (TIGER) drive innovation. Global collaborations via trials like STEER exemplify higher ed's role.

Future Horizons: Autoimmune, Oncology, and Beyond

Predictions: Shift to autoimmunity, in vivo CAR-T, gene writing. Conferences like CGT Summit 2026 spotlight this. For academics, opportunities abound in editing, vectors, trials.

In summary, 2026 research reveals gene therapy's maturation, with university breakthroughs paving curative paths for rares and commons alike. As trials scale, ethical delivery and access remain key.

Photo by Ashraful Islam on Unsplash